AACR 2019 Abstract #5101
Key Messages:
- With the advent of Chimeric Antigen Receptor (CAR) T cell therapy to treat cancer, a new category of targetable biomarkers has emerged that are associated with the surface of malignant cells and serve as targets for cytotoxic T cells
- By modeling target mRNA expression from large scale genomic datasets, selection of targets with desirable properties can be used to maximize patient coverage
- We showed that with 5-7 CAB-CAR-T products it is possible to treat 90% of patients with solid tumor malignancies
